Latest Grifols S.A. Stories
- Three-year commitment of up to 20 million units per year of blood clotting medicines to treat hemophilia patients in developing countries BARCELONA, Spain, April 17, 2014 /PRNewswire/
BARCELONA, Spain, April 4, 2014 /PRNewswire/ -- Grifols, S.A.
Reportbuyer.com just published a new market research report:
BARCELONA, Spain, June 3, 2011 /PRNewswire/ -- Grifols, S.A. (NASDAQ: GRFS) ("Grifols") a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that on June 1, 2011, Grifols completed its acquisition of Talecris Biotherapeutics Holdings Corp.
RESEARCH TRIANGLE PARK, N.C., June 1, 2011 /PRNewswire/ -- Grifols, S.A. (GRF.MC) and Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) announced today that the U.S.
- A pivoted catch designed to fall into a notch on a ratchet wheel so as to allow movement in only one direction (e.g. on a windlass or in a clock mechanism), or alternatively to move the wheel in one direction.